NAD+, NMN and NR: A Research-Based Comparison for Integrative Practitioners

A systematic comparison of NAD+ precursors — NMN vs NR vs niacin vs NMN riboside — covering mechanisms, bioavailability, clinical trial data, dosing, and what naturopathic practitioners need to know in 2026.

This article is for educational and professional reference purposes. NAD+ precursors are supplements, not medicines. This does not constitute clinical advice.

The conversation around NAD+ precursors has matured considerably since the early Sinclair-era excitement. Today, practitioners need more than headlines — they need a rigorous NAD+ NMN NR comparison grounded in human trial data, mechanistic clarity, and clinical applicability. This article provides exactly that: a systematic walkthrough of NMN vs NR and the broader landscape of NAD+ precursors for practitioners working in integrative and naturopathic settings in 2026.

1. NAD+ and Aging: Why It Matters

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. Its central role in redox chemistry, energy production, and genome maintenance has made it one of the most studied molecules in the biology of aging over the past decade.

The age-related decline in NAD+ is well established. Tissue NAD+ levels fall approximately 50% between the ages of 20 and 60, a decline documented in human blood, skin, and muscle biopsies. In skeletal muscle — a metabolically critical tissue — this drop is more pronounced and correlates with functional decline.

Why NAD+ decline matters clinically:

Mitochondrial Complex I function: NAD+ is the primary electron acceptor at Complex I of the mitochondrial electron transport chain. As NAD+ falls, mitochondrial efficiency drops, contributing to fatigue and reduced metabolic capacity.
Sirtuin activation (SIRT1–7): Sirtuins are NAD+-dependent deacylases that regulate gene expression, metabolic adaptation, stress responses, and DNA repair. SIRT1 and SIRT3 are most studied in aging contexts; both require NAD+ as a co-substrate and are directly limited by its availability.
PARP-mediated DNA repair: Poly(ADP-ribose) polymerases (PARPs) consume NAD+ to repair DNA strand breaks. Increased DNA damage in older cells drives PARP hyperactivation, accelerating NAD+ depletion in a self-reinforcing cycle.
CD38 NADase activity: CD38 is an enzyme that degrades NAD+ and increases markedly with age and chronic inflammation. The CD38-driven consumption of NAD+ is now considered a primary driver of age-related NAD+ decline — potentially more significant than reduced biosynthesis in many tissues.

The two competing theories of NAD+ decline:

Decreased production: Reduced activity of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway, leads to lower NAD+ synthesis from nicotinamide.
Increased consumption: PARP overactivation (from cumulative DNA damage) and CD38 upregulation consume NAD+ faster than it can be replenished.

Current evidence supports both mechanisms operating simultaneously, with the relative contribution varying by tissue and individual. This distinction has direct implications for which precursor — and which dosing strategy — is most appropriate.

2. The NAD+ Biosynthesis Pathways

Understanding biosynthesis pathways is not merely academic: it determines which precursor reaches which tissues and at what efficiency.

The Preiss-Handler Pathway (from niacin/nicotinic acid)

Dietary niacin (nicotinic acid, or NA) is converted to NAD+ via a three-step enzymatic pathway: NA → NAMN → NAAD → NAD+. This pathway is distinct from the salvage pathway and does not produce nicotinamide as an intermediate — relevant because nicotinamide at high concentrations inhibits sirtuins (see below). The Preiss-Handler pathway operates efficiently across liver, intestine, and other tissues with high nicotinic acid uptake.

The Salvage Pathway (from NR and NMN)

This is the pathway exploited by most modern NAD+ supplements. Nicotinamide riboside (NR) is phosphorylated by NRK1/NRK2 kinases to form NMN, which is then adenylated by NMNAT enzymes to form NAD+. NMN can also enter the salvage pathway directly — or, as debated in the literature, may first be dephosphorylated back to NR to cross cell membranes.

The salvage pathway is particularly active in tissues with high NAMPT expression (liver, muscle, brain) and is the dominant route for NAD+ replenishment in conditions of depletion.

De Novo Synthesis (from tryptophan)

The kynurenine pathway converts dietary tryptophan to NAD+ via quinolinic acid. This route is slow, metabolically costly (approximately 60 mg of tryptophan per 1 mg of niacin equivalent), and insufficient to meet elevated NAD+ demands in aging or metabolic stress. It matters mainly as a baseline contributor, not as a therapeutic target for supplementation.

Why Pathway Matters for Supplementation Strategy

A practitioner prescribing niacin for lipid management achieves meaningful NAD+ support via the Preiss-Handler pathway — but the flush side effect limits dose. A patient with fatigue and suspected mitochondrial insufficiency may benefit more from NR or NMN entering the salvage pathway, with tissue-specific kinetics. No single pathway is universally superior; the clinical goal determines the entry point.

3. The Four Main NAD+ Precursors Compared

Niacin (Nicotinic Acid)

The oldest and cheapest NAD+ precursor, niacin has decades of cardiovascular safety data. At lipid-therapeutic doses (1–3 g/day), it raises HDL, lowers triglycerides, and modestly elevates tissue NAD+.

Limitation: Prostaglandin-mediated cutaneous vasodilation (the niacin flush) is dose-limiting for most patients. Extended-release formulations reduce but do not eliminate this effect. Hepatotoxicity risk at sustained high doses warrants monitoring. As a NAD+ precursor specifically, niacin is effective but is rarely the optimal choice when flush sensitivity is present or when muscle and brain NAD+ elevation is the primary goal.

Nicotinamide (NAM)

Nicotinamide (niacinamide) is the amide form of niacin. It does not cause flushing and is widely used in skin health and cognitive support formulations.

Critical limitation for NAD+ purposes: Nicotinamide at physiological-to-high concentrations is a product inhibitor of sirtuins — particularly SIRT1. Since one of the primary clinical goals of raising NAD+ is sirtuin activation, supplementing with NAM at doses sufficient to raise NAD+ meaningfully may simultaneously blunt the very signalling benefit practitioners seek. This paradox limits NAM's utility as a standalone NAD+ supplement for longevity-oriented applications, though it remains valuable for other indications.

NR (Nicotinamide Riboside)

NR is the most extensively studied oral NAD+ precursor with human clinical data. It entered the supplement market commercially as Tru Niagen (ChromaDex) and Elysium Basis (paired with pterostilbene).

Key human RCT data:

Trammell et al., 2016 (Nature Communications): The landmark first human pharmacokinetic study. Single doses of 100–300 mg NR in healthy adults increased whole-blood NAD+ in a dose-dependent manner, with NMN and NAAM as metabolites. Demonstrated that oral NR is bioavailable and raises NAD+ metabolomes.
Martens et al., 2018 (Nature Communications): 8-week RCT, 1,000 mg/day NR in middle-aged and older adults (n=30). Blood NAD+ increased approximately 60% versus placebo. Systolic blood pressure reduced in a subgroup with elevated baseline BP. No significant change in mitochondrial biogenesis markers or physical performance in this timeframe — important for managing patient expectations.

NR consistently raises blood NAD+ by 40–60% in human studies. Its safety profile across multiple trials up to 2,000 mg/day is good, with minor GI complaints at higher doses being the most common adverse effect.

NMN (Nicotinamide Mononucleotide)

NMN is positioned one step further along the salvage pathway than NR. It is David Sinclair's publicly stated preferred compound and the subject of significant commercial attention since his 2013 mouse studies.

The cellular entry debate: NMN is a larger molecule than NR and cannot cross cell membranes directly via the same transporters. For years, the prevailing view was that NMN must be dephosphorylated to NR extracellularly before cellular uptake, then re-phosphorylated intracellularly — making NMN effectively a prodrug for NR. In 2019, a specific NMN transporter (Slc12a8) was identified in mouse intestinal cells, suggesting some tissues may take up NMN intact. Whether this transporter operates in humans and at what scale remains an active research question.

Practically, this debate matters less than it once appeared: Both NR and NMN raise tissue NAD+. The question is whether NMN does so more efficiently or preferentially in certain tissues.

Key human RCT data:

Yoshino et al., 2021 (Science): 10-week RCT, 250 mg/day NMN in postmenopausal women with prediabetes (n=25). NMN improved skeletal muscle insulin signalling and muscle NAD+ metabolism (assessed via muscle biopsies). No significant change in blood NAD+ was found — suggesting NMN may preferentially elevate muscle NAD+ without large changes in circulating levels, a finding with important implications for how practitioners interpret blood NAD+ tests.
Igarashi et al., 2022 (NPJ Aging): 12-week RCT, 250 mg/day NMN in healthy older adults (n=30). Improvements in gait speed and grip strength compared to placebo, alongside blood NAD+ elevation. Suggested functional benefits at lower doses in older adults.
Multiple additional safety studies (Irie 2020, Yi et al. 2023) confirm tolerability at doses up to 1,200 mg/day without significant adverse events.

4. NMN vs NR: The Clinical Evidence Head-to-Head

For practitioners making prescribing decisions, the honest NMN vs NR comparison in 2026 looks like this:

What the evidence shows:

| Parameter | NR | NMN | |---|---|---| | Blood NAD+ elevation | 40–60% (well replicated) | Variable; may be lower in blood, higher in muscle | | Number of human RCTs | More (6+ published) | Fewer (4–5 published) | | Muscle-specific data | Limited | Yoshino 2021 shows muscle NAD+ benefit | | Functional outcomes | Limited (BP subgroup) | Igarashi 2022: gait/grip improvement | | Head-to-head RCT | Not yet conducted | — | | Commercially available in AU | Yes | Yes | | Cost | Moderate | Higher |

The critical gap: No published randomised controlled trial has directly compared NR to NMN with clinical outcome measures in the same population. All comparative claims in supplement marketing are extrapolated from separate trials in different populations — a major limitation.

Practitioner recommendation framework:

For patients seeking well-evidenced blood NAD+ elevation with established safety data: NR 500–1,000 mg/day is the evidence-anchored choice.
For patients with primary muscle-related concerns (fatigue, sarcopenia risk, metabolic syndrome with insulin resistance): NMN may have an advantage based on Yoshino et al., though evidence remains preliminary.
For older adults where physical function is the primary outcome: NMN data (Igarashi) is modestly encouraging.
Monitor blood NAD+ if using NMN — the Yoshino data suggests plasma levels may not reflect tissue accumulation, so clinical symptom tracking matters as much as biomarker testing.

5. David Sinclair's NMN Protocol and the Research Behind It

David Sinclair (Harvard Medical School) has been the most publicly visible proponent of NMN supplementation. His personal protocol — 1 g/day NMN, 1 g/day resveratrol, and metformin — has been widely discussed in popular media and warrants careful analysis.

The mouse data foundation:

Sinclair's 2013 Cell paper showed that NMN supplementation reversed vascular and muscle aging in mice. Subsequent work demonstrated improvements in energy metabolism, exercise capacity, and lifespan extension in specific mouse models. The Interventions Testing Program (ITP) — a rigorous NIA-funded multi-site mouse longevity trial — has not shown statistically significant lifespan extension with NMN to date, though metabolic benefits in aged mice have been reported in other labs.

Why animal data does not directly translate:

Mice have fundamentally different NAD+ pharmacokinetics from humans. Mouse intestinal NMN absorption and the Slc12a8 transporter expression pattern may differ materially from humans. Mice also age on a timescale that compresses decades of human aging into months — NMN's effects on mouse lifespan cannot be assumed to translate to equivalent effects on human aging trajectories.

What 2021–2026 human trials actually show:

The human data shows that NMN at 250–1,200 mg/day is safe, raises NAD+ (in blood and likely muscle), and produces modest improvements in specific functional markers (insulin sensitivity, gait speed) in middle-aged and older adults. There is currently no published human trial showing NMN extends lifespan, reverses aging, or produces the dramatic rejuvenating effects seen in rodent models.

On resveratrol: The combination with resveratrol in Sinclair's personal stack is based on the hypothesis that resveratrol activates SIRT1, which then requires NAD+ (provided by NMN) to function. However, the resveratrol-SIRT1 direct activation hypothesis has been substantially challenged since 2010, and the human RCT data for resveratrol's NAD+/sirtuin pathway is not robust. Practitioners should evaluate NMN independently of resveratrol claims.

On metformin: Sinclair includes metformin as an AMPK activator and potential longevity agent. The TAME trial (Targeting Aging with Metformin) is ongoing. Notably, metformin may blunt the exercise-induced NAD+ response — a potential concern for patients who are physically active.

6. Dosage: What Human Trials Use

Dosing decisions should be anchored to published human pharmacokinetic and intervention data, not to animal studies.

NR Dosing in Human Trials:

250 mg/day: Minimal threshold; used in some safety studies
500–1,000 mg/day: Standard range in most published RCTs; Martens 2018 used 1,000 mg/day
2,000 mg/day: Highest dose in safety studies; ChromaDex Phase 1 data shows tolerability with mild GI effects
Duration: A minimum of 8 weeks appears necessary for meaningful physiological effects; most RCTs run 8–12 weeks
Timing: Human pharmacokinetic data does not strongly favour a specific time of day; with food may reduce GI discomfort at higher doses

NMN Dosing in Human Trials:

250 mg/day: Yoshino 2021 and Igarashi 2022 — lowest effective dose in published trials; showed tissue-level and functional benefits
500–1,200 mg/day: Used in more recent dose-escalation and safety studies
Safety ceiling: Irie et al. 2020 (first human NMN safety study, single doses up to 500 mg) and subsequent studies confirm safety; no serious adverse events reported up to 1,200 mg/day in published data
Duration: Effects on skeletal muscle insulin sensitivity (Yoshino) evident at 10 weeks; functional outcomes (Igarashi) at 12 weeks

Practitioner guidance:

Start conservatively at 250–500 mg/day for either compound in new users, particularly those over 65 or with hepatic concerns. Titrate based on clinical response and tolerability over 4–6 weeks before assessing outcomes.

7. Bioavailability and Formulation

Sublingual NMN:

One frequently cited study (by manufacturers producing sublingual NMN products) reported higher plasma NMN levels with sublingual administration compared to oral capsules, hypothesising that sublingual delivery bypasses first-pass hepatic metabolism. If the cellular entry debate means NMN is substantially converted to NR in the gut wall or liver before reaching peripheral tissues, sublingual delivery could theoretically preserve more intact NMN. However, this data comes from manufacturer-funded studies and has not been independently replicated. Sublingual NMN products typically cost significantly more than oral capsules.

Enteric-coated NR:

Some NR products use enteric coating to delay release until the small intestine, aiming to reduce gastric degradation of NR. The pharmacokinetic benefit of enteric coating over standard capsules has not been conclusively demonstrated in peer-reviewed head-to-head studies.

Liposomal formulations:

Liposomal NR and NMN products are marketed with claims of superior absorption. Independent evidence for meaningful bioavailability advantage over standard capsule formulations is lacking in the published literature as of 2026.

Storage:

Both NR and NMN are sensitive to heat, moisture, and light. NAD+ precursors should be stored in a cool, dry location — refrigeration is advisable for NMN powder products. Many capsule-form products are shelf-stable at room temperature if kept away from humidity and direct light. Practitioners should advise patients to check manufacturer storage guidance, particularly in Australia's warmer climate.

Product availability in Australia:

NR (as Tru Niagen and generic NR) is widely available through Australian supplement retailers and online. NMN is increasingly available through specialist supplement suppliers. Practitioners should advise patients to select products from manufacturers with third-party testing (COA documentation), as quality varies substantially. The TGA does not currently regulate NAD+ precursors as scheduled medicines, but therapeutic goods standard obligations apply to therapeutic claims.

8. Clinical Applications in Naturopathic Practice

Mitochondrial Insufficiency and Fatigue

Patients presenting with persistent fatigue, reduced exercise capacity, or suspected mitochondrial dysfunction represent one of the clearest clinical rationales for NAD+ precursor support. Mitochondrial Complex I dependence on NAD+ means that declining NAD+ availability directly translates to reduced ATP production efficiency. NR or NMN alongside CoQ10 and magnesium glycinate addresses multiple points of mitochondrial support simultaneously — for the evidence on CoQ10 form selection, statin depletion, and cardiovascular outcomes, see the CoQ10 vs ubiquinol clinical prescribing guide. NAD+ also sits at the centre of the autophagy regulatory network: sirtuin activation by NAD+ directly promotes mitophagic flux, and AMPK — activated by fasting and caloric restriction that also raises NAD+ ratios — is the primary upstream switch for autophagic initiation. Practitioners designing longevity protocols will find the mechanistic overlap covered in depth in the autophagy, fasting, and longevity clinical framework.

Researchers investigating NAD+ pathways alongside NAD-supporting peptide research have identified overlapping mechanisms — peptides under investigation appear to support mitochondrial biogenesis through pathways that intersect with NAD+/SIRT1 signalling, making this an area of emerging integrative interest for practitioners following the research frontier.

Cognitive Aging

Brain NAD+ decline has been linked to reduced SIRT1 activity in neurons and impaired neuronal repair capacity. Preclinical data is extensive; human trial data for cognitive outcomes specifically is limited but encouraging. NR at 1,000 mg/day has been used in small human trials targeting cognitive endpoints in older adults, with modest positive signals. This remains an active research area rather than an established clinical application.

Metabolic Syndrome and Insulin Resistance

The Yoshino 2021 data — showing NMN improved skeletal muscle insulin signalling in prediabetic postmenopausal women — is the strongest human evidence for metabolic application of NMN specifically. Practitioners managing patients with metabolic syndrome, insulin resistance, or risk of type 2 diabetes have the most direct human trial support for NMN in this application. NR's metabolic effects are less specifically characterised in human trials.

Athletic Recovery and Exercise Adaptation

Skeletal muscle NAD+ is essential for exercise-induced mitochondrial biogenesis and repair. Whether supplemental NAD+ precursors enhance these adaptations in already-healthy younger athletes is uncertain — most positive data comes from middle-aged or older study participants. However, older recreational athletes (50+) or those with reduced exercise tolerance may represent an appropriate use case.

Hormonal and Endocrine Support

NAD+ is required for SIRT1 activity, which regulates FOXO transcription factors, inflammatory signalling (NF-κB), and stress hormone responses. Practitioners incorporating the DUTCH test for comprehensive hormone assessment may find NAD+ precursor support a useful adjunct when mitochondrial stress markers or cortisol dysregulation are identified, given SIRT1's role in cortisol metabolism and adrenal function. It is also worth noting that NAD+ biosynthesis involves SAMe-dependent methylation steps; patients with significant MTHFR polymorphisms and impaired methylation capacity may have reduced upstream SAMe availability affecting multiple biosynthetic pathways — for a full clinical protocol covering this intersection, see the MTHFR mutations and methylation naturopathic guide.

Adaptogenic Combinations

In patients with high allostatic load, NAD+ precursors may complement adaptogenic protocols. Ashwagandha's clinical evidence includes effects on cortisol, fatigue, and thyroid function — systems where NAD+/sirtuin pathways also operate. Combining a mitochondrial support stack (NR or NMN + CoQ10) with ashwagandha is rational in fatigued patients with both HPA axis dysregulation and suspected mitochondrial insufficiency.

Patient Education Framework

When introducing NAD+ precursors to patients:

Set realistic expectations: these are not acute-effect supplements; changes develop over 8–12 weeks minimum
Explain the mechanism at a level appropriate to health literacy — for example: "this helps your cells produce energy more efficiently and supports DNA repair"
Establish baseline markers where possible (CMP, fasting glucose, subjective fatigue scoring)
Review at 8–12 weeks with objective and subjective measures
Consider a trial pause after 3–6 months to assess whether benefits are maintained

9. Safety and Interactions

General Safety Profile

NAD+ precursors have a strong short-to-medium term safety record in human trials. The most common adverse effects are mild GI symptoms (nausea, loose stools) at higher doses, particularly NR above 1,000 mg/day. No serious adverse events have been reported in published human RCTs at doses up to 2,000 mg/day NR or 1,200 mg/day NMN.

Theoretical Cancer Concern

NAD+ supports DNA repair via PARPs, and elevated NAD+ could theoretically support cancer cell metabolism, which is highly NAD+-dependent. This concern has been raised in the scientific literature and warrants patient-specific consideration. Practitioners should exercise caution with NAD+ precursors in patients with active malignancies or known cancer predisposition syndromes until further research clarifies the oncological safety profile. This is a precautionary recommendation, not an established contraindication.

Nausea at Higher Doses

NR above 1,000 mg/day and NMN above 500 mg/day may cause nausea, particularly when taken on an empty stomach. Advising patients to take with a small meal generally resolves this.

Drug Interactions

Metformin: Metformin may attenuate exercise-induced mitochondrial adaptation. The clinical significance of combining metformin with NAD+ precursors is not established; Sinclair uses this combination but no clinical trial has evaluated the combination prospectively.
Alcohol: Both NAD+ and alcohol metabolism involve NADH/NAD+ redox cycling. Heavy alcohol use chronically depletes hepatic NAD+; NAD+ precursor support is theoretically beneficial in recovery settings, though this is not an established clinical application.
Warfarin: Niacin (not NR or NMN) has known interactions with warfarin. No significant interactions between NR or NMN and anticoagulants are currently documented, but monitoring is appropriate until further data emerges.
Antibiotics: Some evidence suggests gut microbiome involvement in NR metabolism. Concurrent antibiotic use may transiently alter NR pharmacokinetics; the clinical significance is unknown.

Long-Term Safety

Published human trial durations extend to 12 weeks in most cases, with a small number of open-label extensions. Long-term safety data beyond 12 months in humans is limited. The extended rodent data is reassuring, but practitioners should set realistic expectations with patients and incorporate periodic reassessment.

10. Frequently Asked Questions

Is NMN or NR better?

There is no definitive answer — and any practitioner or product claiming otherwise is overstating the current evidence. NR has more published human RCTs and better-replicated blood NAD+ elevation data. NMN has more compelling preliminary data for muscle NAD+ and insulin sensitivity specifically (Yoshino 2021). For most patients seeking general NAD+ support with established evidence, NR is the more conservatively evidence-based choice. For patients with muscle-related metabolic concerns, NMN may have an edge. The best NAD+ precursor is ultimately the one the patient will take consistently, as both raise NAD+ via the salvage pathway.

How long does NMN take to work?

Based on published trial data, meaningful physiological changes occur over 8–12 weeks of consistent supplementation. Subjective improvements in energy or exercise capacity may be noticed earlier (4–6 weeks in some patients) but should not be expected as an acute effect. Blood NAD+ levels rise within days of starting supplementation, but downstream biological changes that produce clinical outcomes require weeks to months.

Can I get NAD+ from food?

Dietary NAD+ exists in foods (milk, meat, fish, edamame) primarily as NR and NMN bound in larger molecules. Dietary intake contributes only modestly to tissue NAD+ levels — sufficient for baseline metabolic function in youth, but insufficient to offset age-related decline at therapeutic intent. Cow's milk contains detectable NR and contributed to early interest in NR as a supplement. However, concentrations achievable through diet alone are orders of magnitude below supplement doses used in clinical trials.

Is NAD+ supplementation safe long-term?

The available human data (up to 12 weeks in RCTs) shows an excellent safety profile for both NR and NMN. Long-term safety data beyond one year is limited, which is a genuine knowledge gap. The theoretical cancer concern warrants case-by-case assessment. In healthy middle-aged to older adults without oncological risk factors, continued supplementation with periodic reviews (every 6 months) represents a reasonable approach given the current evidence base.

What is the best NMN supplement in Australia?

Practitioners should guide patients toward products that provide: (a) third-party Certificate of Analysis (COA) confirming purity and stated dose; (b) GMP-certified manufacturing; (c) appropriate storage and packaging (opaque, moisture-controlled). Brand premium is not a reliable indicator of product quality. Australian consumers can access both NR (as Tru Niagen, widely available) and NMN through specialist supplement retailers. Powder-form NMN from reputable suppliers with independent testing is often more cost-effective than branded capsule products, though capsule convenience supports adherence.

Should NAD+ precursors be cycled?

There is no evidence from human trials for or against cycling. Anecdotal reports of benefit from cycling (e.g., 5 days on, 2 days off, or 3 months on, 1 month off) exist in the practitioner community but lack trial support. Consistent daily use reflects the protocols used in published research and is the approach most supported by existing evidence.

Key Takeaways for Practitioners

The NAD+ NMN NR comparison landscape in 2026 is more nuanced than either enthusiastic supplement marketing or dismissive scepticism suggests. Human trial evidence supports the following evidence-anchored conclusions:

Both NR and NMN safely and meaningfully raise NAD+ in humans at doses of 250–1,000 mg/day
NR has more published RCT replications for blood NAD+ elevation
NMN may preferentially benefit skeletal muscle NAD+ and insulin sensitivity
No head-to-head clinical outcomes trial exists; comparative claims are extrapolated, not direct
Minimum 8–12 weeks of supplementation is required to assess clinical benefit
The cancer proliferation concern warrants individualised risk assessment
Formulation hype (sublingual, liposomal) is ahead of independent evidence

For practitioners integrating NAD+ precursor support into patient protocols, the goal is not chasing longevity headlines but addressing specific physiological deficits — mitochondrial inefficiency, metabolic dysfunction, or cognitive aging — with appropriately dosed, quality-assured compounds monitored through both objective biomarkers and patient-reported outcomes.

References available on request. Key sources: Trammell et al., Nature Communications (2016); Martens et al., Nature Communications (2018); Yoshino et al., Science (2021); Igarashi et al., NPJ Aging (2022); Irie et al., Endocrine Journal (2020); Bogan & Brenner, Annual Review of Nutrition (2008); Camacho-Pereira et al., Cell Metabolism (2016).